Covidien has invested over $150 million in the Hobart facility since 1996, including oral non-sterile liquid production, high-speed encapsulation and tablet presses.
This image is to illustrate the Covidien Pharmaceuticals Outsourcing company profile. From here you can view the profile or send an enquiry.
Copyright 2008 SPG Media Limited a subsidiary of SPG Media Group PLC
